CGEM — Cullinan Therapeutics, Inc. stock price, charts and financials

QT86Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
18.15
+0.42+2.37%
OverviewShort InterestFilings
CGEMQT86Cullinan Therapeutics, Inc.·NASDAQ
18.15+2.37%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.02%$15.53MESO+4.33%$16.63ZBIO-1.09%$32.08GHRS-1.37%$29.86TSHA-1.75%$6.45STOK-1.62%$32.18ABCL+35.57%$9.39VRDN-2.37%$23.03
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand61.46MPerf Week7.45%
Market Cap1.09BForward P/E-EPS next Y-2.41Insider Trans-0.23%Shs Float44.16MPerf Month-3.54%
Enterprise Value1.01BPEG-EPS next Q-Inst Own-Short Float23.30%Perf Quarter20.45%
Income-204.53MP/S0.00EPS this Y-Inst Trans-Short Ratio9.66Perf Half Y49.62%
Sales0.00P/B3.39EPS next Y20.51%ROA-56.27%Short Interest10.29MPerf YTD71.30%
Book/sh-P/C-EPS next 5Y-ROE-52.89%52W High19.89 -8.75%Perf Year125.00%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-68.50%52W Low5.81 212.15%Perf 3Y72.64%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.75% 5.53%Perf 5Y-22.68%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-8.04%Oper. Margin0.00%ATR (14)1.00Perf 10Y-
Dividend Ex-Date-Quick Ratio8.42Sales Y/Y TTM-Profit Margin0.00%RSI (14)54.30Recom2.00
Dividend Gr. 3/5Y-Current Ratio8.42EPS Q/Q-1.35%SMA201.79%Beta0.02Target Price33.50
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA506.97%Rel Volume0.36Prev Close17.73
Employees109LT Debt/Eq0.00EarningsNov 05SMA20033.48%Avg Volume996.35KPrice18.15
IPO DateJan 08, 2021Option/ShortYes / YesEPS/Sales Surpr.10.27% -Net Debt/EBITDA0.37Volume361,734Change2.37%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-29-26ReiteratedBTIGBuy$38 → $39
May-08-26ReiteratedWedbushOutperform$36 → $37
Apr-28-26ReiteratedHC Wainwright & Co.Buy$27 → $30
Mar-11-26ReiteratedWedbushOutperform$34 → $36
Mar-10-26ReiteratedStifel Nicolaus$28
Feb-02-26InitiatedGuggenheimBuy$30
Jan-08-26ReiteratedMorgan StanleyOverweight$28 → $30
Jan-08-26ReiteratedHC Wainwright & Co.Buy$28 → $27
Dec-09-25ReiteratedWedbushOutperform$34
Nov-24-25ReiteratedBTIGBuy$32 → $38
Latest News
Company

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
000—————
Cost of Goods Sold Incl. D&A
000—————
Gross Profit
000—————
Selling, General and Administrative Excl. Other545442—————
Research and Development187143148—————
Other Operating Expense101—————
Operating Income-242-197-191—————
Interest Expense
000—————
Unusual Expense
————————
Non-Operating Income (Expense)222922—————
Net Income Before Taxes-220-167-169—————
Income Taxes00-14—————
Consolidated Net Income-220-167-153—————
Net Income From Continuing Operations-220-168-155—————
Net Income-220-167-153—————
EPS (Recurring)-3.72-3.11-3.69—————
EPS (Basic, Before Extraordinaries)-3.72-3.11-3.69—————
EPS (Diluted)-3.72-3.11-3.69—————
EBITDA-220-167-190—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio
————————
Gross Margin
————————
Operating Margin
————————
Net Margin
————————
Shares Outstanding595442—————
Market Capitalization611658428—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$20.39$16.25$12.12$7.98$3.84● Close Price0.00M3.33M6.66M9.99M13.32MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Michaelson JenniferChief Scientific OfficerJul 06 '26Option Exercise4.304,00017,200170,844Jul 07
Michaelson JenniferChief Scientific OfficerJul 06 '26Sale17.828,000142,560162,844Jul 07
Michaelson JenniferChief Scientific OfficerMay 05 '26Option Exercise4.304,00017,200174,844May 06
Michaelson JenniferChief Scientific OfficerMay 05 '26Sale14.628,000116,996166,844May 06
Michaelson JenniferChief Scientific OfficerMar 05 '26Sale15.688,000125,440170,844Mar 09
Michaelson JenniferChief Scientific OfficerMar 05 '26Option Exercise4.304,00017,200178,844Mar 09
Michaelson JenniferChief Scientific OfficerFeb 25 '26Sale14.141,78025,169174,844Feb 26
Jones Jeffrey AlanChief Medical OfficerFeb 24 '26Sale14.474,58266,302159,968Feb 25
SUMER JACQUELYN LChief Legal OfficerFeb 24 '26Sale14.473,60152,106128,089Feb 25
Michaelson JenniferChief Scientific OfficerFeb 24 '26Sale14.473,60152,106176,624Feb 25
AHMED NADIMPresident and CEOFeb 24 '26Sale14.4713,515195,562390,803Feb 25
Michaelson JenniferChief Scientific OfficerFeb 23 '26Sale13.991,75224,510180,225Feb 25
Michaelson JenniferChief Scientific OfficerFeb 20 '26Sale14.0811,742165,366181,977Feb 23
Jones Jeffrey AlanChief Medical OfficerFeb 20 '26Sale13.624,98267,855164,550Feb 23
Michaelson JenniferChief Scientific OfficerFeb 20 '26Option Exercise4.308,00034,400189,977Feb 23
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.